Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

featured

Published in Obesity, Metabolic Syndrome, and Prediabetes and

Journal Scan / Research · February 12, 2024

Glucagon Secretion and Its Association With Glycaemic Control and Ketogenesis During SGLT2 Inhibition by Ipragliflozin in People With Type 1 Diabetes

Diabetes, Obesity & Metabolism

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Carolina Gonzalez-Lopez MD

David Mathiesen MD

Casper Nielsen MSc, PhD

Diabetes, Obesity & Metabolism

Glucagon secretion and its association with glycaemic control and ketogenesis during sodium-glucose cotransporter 2 inhibition by ipragliflozin in people with type 1 diabetes: Results from the multicentre, open-label, prospective study

Diabetes Obes Metab 2024 Jan 22;[EPub Ahead of Print], Y Nakamura, I Horie, T Kitamura, Y Kusunoki, K Nishida, A Yamamoto, Y Hirota, T Fukui, Y Maeda, M Minami, T Matsui, A Kawakami, N Abiru

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Obesity, Metabolic Syndrome, and Prediabetes

Glucagon Secretion and Its Association With Glycaemic Control and Ketogenesis During SGLT2 Inhibition by Ipragliflozin in People With Type 1 Diabetes

Additional Info

Glucagon secretion and its association with glycaemic control and ketogenesis during sodium-glucose cotransporter 2 inhibition by ipragliflozin in people with type 1 diabetes: Results from the multicentre, open-label, prospective study

Further Reading

The Burden of Diabetes-Associated Multiple Long-Term Conditions on Years of Life Spent and Lost

Impact of GLP-1 Receptor Agonist–Based Treatments on Fat-Free Mass

Association Between Ultraprocessed Food Consumption and the Risk of Diabetes

Association of Glycaemic Risk Factors and Diabetes Duration With the Risk of Heart Failure in People With Type 2 Diabetes

Outcomes of Time-Restricted Eating in Adults With Metabolic Syndrome

Impact of Overweight and Obesity on Health Outcomes in the US From 1990 to 2021

The Effect of Semaglutide on Mortality and COVID-19–Related Deaths

Impact of GLP-1 RAs on Cardiorenal Outcomes and Mortality in People With Type 2 Diabetes and Acute Kidney Disease

SGLT2 Inhibitors in Hospitalised Patients With COVID-19

Degree of Joint Control of Risk Factors and Incident Chronic Kidney Disease Among Individuals With Obesity

Progression of Obesity-Related Complications Over 10 Years in a Population With Overweight and Obesity

Recently Updated